The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Aged 6 - 24 years
Medical records available
Diagnosis of MDD, anxiety disorder, or OCD
Current or past history of SSRI therapy
Inability of parent/legal guardian to give informed consent
Inability of the child to give informed assent
Unwillingness of child to provide saliva sample for genetic analysis
Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.
University of Calgary
Lead sponsor
Hotchkiss Brain Institute, University of Calgary
Collaborator
Alberta Health services
Collaborator